These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25190128)

  • 1. Neutrophil-lymphocyte ratio is a simple and novel biomarker for prediction of survival after radioembolization for metastatic colorectal cancer.
    Tohme S; Sukato D; Chalhoub D; McDonald KA; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
    Ann Surg Oncol; 2015 May; 22(5):1701-7. PubMed ID: 25190128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization.
    Sukato DC; Tohme S; Chalhoub D; Han K; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
    J Vasc Interv Radiol; 2015 Jun; 26(6):816-24.e1. PubMed ID: 25824315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients.
    Saxena A; Meteling B; Kapoor J; Golani S; Morris DL; Bester L
    Ann Surg Oncol; 2015 Mar; 22(3):794-802. PubMed ID: 25323474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Survival after Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases.
    Weiner AA; Gui B; Newman NB; Nosher JL; Yousseff F; Lu SE; Foltz GM; Carpizo D; Lowenthal J; Zuckerman DA; Benson B; Olsen JR; Jabbour SK; Parikh PJ
    J Vasc Interv Radiol; 2018 Aug; 29(8):1094-1100. PubMed ID: 29754852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative neutrophil to lymphocyte ratio predicts survival in patients with T1-2N0 colorectal cancer.
    Shin JS; Suh KW; Oh SY
    J Surg Oncol; 2015 Nov; 112(6):654-7. PubMed ID: 26437893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.
    McNally ME; Martinez A; Khabiri H; Guy G; Michaels AJ; Hanje J; Kirkpatrick R; Bloomston M; Schmidt CR
    Ann Surg Oncol; 2013 Mar; 20(3):923-8. PubMed ID: 22965570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer.
    Rossi L; Santoni M; Crabb SJ; Scarpi E; Burattini L; Chau C; Bianchi E; Savini A; Burgio SL; Conti A; Conteduca V; Cascinu S; De Giorgi U
    Ann Surg Oncol; 2015 Apr; 22(4):1377-84. PubMed ID: 25234022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer.
    Shibutani M; Maeda K; Nagahara H; Noda E; Ohtani H; Nishiguchi Y; Hirakawa K
    Anticancer Res; 2013 Aug; 33(8):3291-4. PubMed ID: 23898094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal cancer patients receiving oxaliplatin-based chemotherapy.
    Kaneko M; Nozawa H; Sasaki K; Hongo K; Hiyoshi M; Tada N; Murono K; Nirei T; Kawai K; Sunami E; Tsuno NH; Kitayama J
    Oncology; 2012; 82(5):261-8. PubMed ID: 22538399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated neutrophil to lymphocyte ratio might predict poor prognosis for colorectal liver metastasis after percutaneous radiofrequency ablation.
    Zhang Y; Peng Z; Chen M; Liu F; Huang J; Xu L; Zhang Y; Chen M
    Int J Hyperthermia; 2012; 28(2):132-40. PubMed ID: 22335227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after gastroenterostomy in patients with advanced pancreatic adenocarcinoma.
    Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Okamura Y
    Ann Surg Oncol; 2013 Dec; 20(13):4330-7. PubMed ID: 23982254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
    Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
    J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Low Neutrophil to Lymphocyte Ratio Before Preoperative Chemotherapy Predicts Good Outcomes After the Resection of Colorectal Liver Metastases.
    Mao R; Zhao JJ; Bi XY; Zhang YF; Li ZY; Huang Z; Zhou JG; Zhao H; Cai JQ
    J Gastrointest Surg; 2019 Mar; 23(3):563-570. PubMed ID: 30066069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
    Hendlisz A; Van den Eynde M; Peeters M; Maleux G; Lambert B; Vannoote J; De Keukeleire K; Verslype C; Defreyne L; Van Cutsem E; Delatte P; Delaunoit T; Personeni N; Paesmans M; Van Laethem JL; Flamen P
    J Clin Oncol; 2010 Aug; 28(23):3687-94. PubMed ID: 20567019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients.
    Saxena A; Kapoor J; Meteling B; Morris DL; Bester L
    Ann Surg Oncol; 2014 Apr; 21(4):1296-303. PubMed ID: 24337647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Therasphere Radioembolization for Colorectal Metastases.
    Abbott AM; Kim R; Hoffe SE; Arslan B; Biebel B; Choi J; El-Haddad G; Kis B; Sweeney J; Meredith KL; Almhanna K; Strosberg J; Shibata D; Fulp WJ; Shridhar R
    Clin Colorectal Cancer; 2015 Sep; 14(3):146-53. PubMed ID: 25795047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?
    Sangha BS; Nimeiri H; Hickey R; Salem R; Lewandowski RJ
    Curr Treat Options Oncol; 2016 Jun; 17(6):26. PubMed ID: 27098532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
    Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.
    Sunakawa Y; Yang D; Cao S; Zhang W; Moran M; Astrow SH; Hsiang J; Stephens C; Tsuji A; Takahashi T; Tanioka H; Negoro Y; Takagane A; Tani S; Yamaguchi T; Eto T; Fujii M; Ichikawa W; Lenz HJ
    Clin Colorectal Cancer; 2018 Dec; 17(4):e741-e749. PubMed ID: 30219280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neutrophil-to-lymphocyte ratio as a predictor for recurrence of colorectal liver metastases following radiofrequency ablation.
    Chang Z; Zheng J; Ma Y; Zhao J; Wang C; Liu Z
    Med Oncol; 2014 Mar; 31(3):855. PubMed ID: 24477649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.